Displaying 31–40 of 236 research results
Feb 8, 2022
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Interim results for pediatric patients with CNGB3 mutations were encouraging
Feb 1, 2022
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
This new treatment can reduce the frequency of injections into the eye
Jan 28, 2022
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
The Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
Jan 19, 2022
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Company seeks to out-license its retinal progenitor therapy to a partner
Jan 18, 2022
Foundation Seeks My Retina Tracker Registry Members with X-Linked Retinitis Pigmentosa for Research Survey
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
Jan 7, 2022
Foundation’s RD Fund Invests in SalioGen Therapeutics, Developer of Novel Gene Coding Technology for Treating Inherited Retinal Diseases
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
Dec 13, 2021
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
Oct 25, 2021
FDA Approves Genentech’s Susvimo for Treating Wet AMD
The approach significantly reduces the need for regular ocular injections.
Oct 18, 2021
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
The emerging gene therapy is being designed to more safely reach the fovea